PMD Clinical Trial
In the winter of 2009/10, UCSF Children's Hospital will begin a Phase I safety study sponsored by StemCells, Inc. for a potential new therapy for connatal Pelizaeus-Merzbacher Disease (PMD), which is a rare inherited condition involving the central nervous system. Children with PMD are unable to form myelin. As a result, children have impaired function in language development and memory, and delayed motor skills seen as poor coordination and the inability to walk.
Learn more about Pelizaeus-Merzbacher Disease (PMD)
Children found eligible for the study will undergo an operation that implants human central nervous system stem cells (HuCNS-SC® cells) into their brain. The study will examine whether HuCNS-SC® cells can be safely transplanted in children with a myelin disorder. The research is designed to see whether treatment with stem cells might one day help PMD patients. The HuCNS-SC® cells to be used in the trial are being supplied by StemCells, Inc.
for more information about this study Click here
http://neonatology.ucsf.edu/nbri/pmd-trial/default.aspx
